T-Cypher Bio
4 known investors
T-Cypher develops drugs against novel disease-specific targets to treat patients with cancer and autoimmune diseases, focusing on immune-system-engaging medicines. Its approach combines proprietary wet-lab and computational platforms to study cellular communication and identify new therapeutic targets.
AI & Machine LearningBiotechDeep Tech
Investors · 4
Frequently asked questions
- What does T-Cypher Bio do?
- T-Cypher develops drugs against novel disease-specific targets to treat patients with cancer and autoimmune diseases, focusing on immune-system-engaging medicines. Its approach combines proprietary wet-lab and computational platforms to study cellular communication and identify new therapeutic targets.
- Who are T-Cypher Bio's investors?
- T-Cypher Bio's investors include Future Planet Capital, LifeArc Ventures, Oxford Science Enterprises, Perivoli Innovations.